SEARCH

SEARCH BY CITATION

References

  • 1
    Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 25560.
  • 2
    Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 2002; 16(Suppl. 4): 214.
  • 3
    Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther 2004; 20(Suppl. 4): 97101.
  • 4
    Gisbert JP, Gomollon F, Mate J, Pajares JM. Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterol Hepatol 2002; 25: 40115.
  • 5
    Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2000;(2):CD000545.
  • 6
    Ghosh S, Chaudhary R, Carpani M, Playford RJ. Is thiopurine therapy in ulcerative colitis as effective as in Crohn’s disease? Gut 2006; 55: 68.
  • 7
    Ginsburg PM, Dassopoulos T. Steroid dependent ulcerative colitis: azathioprine use is finally “evidence-based”. Inflamm Bowel Dis 2006; 12: 9212.
  • 8
    Ohno K, Masunaga Y, Ogawa R, Hashiguchi M, Ogata H. A systematic review of the clinical effectiveness of azathioprine in patients with ulcerative colitis. Yakugaku Zasshi 2004; 124: 55560.
  • 9
    Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007 Jan 24;(1):CD000478.
  • 10
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 11
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 55760.
  • 12
    Pikarsky A, Zmora O, Wexner SD. Immunosuppressants and operation in ulcerative colitis. J Am Coll Surg 2002; 195: 25160.
  • 13
    Asakura H. Role and side-effects of TPMT polymorphisms of 6-MP and azathioprine in the treatment of steroid-resistant and -dependent ulcerative colitis. J Gastroenterol 2003; 38: 8069.
  • 14
    Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2: 4107.
  • 15
    Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 11238.
  • 16
    Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004; 16: 140713.
  • 17
    Glas J, Torok HP, Daczo J, Tonenchi L, Folwaczny M, Folwaczny C. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur J Med Res 2005; 10: 5358.
  • 18
    Hande S, Wilson-Rich N, Bousvaros A, et al. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006; 12: 2517.
  • 19
    Banerjee S, Bishop WP. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center. J Pediatr Gastroenterol Nutr 2006; 43: 32430.
  • 20
    Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 24989.
  • 21
    Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 158792.
    Direct Link:
  • 22
    Actis GC, Bresso F, Astegiano M, et al. Safety and efficacy of azathioprine in the maintenance of ciclosporin- induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001; 15: 130711.
  • 23
    Domenech E, Garcia-Planella E, Bernal I, et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 20615.
  • 24
    Actis GC, Pinna-Pintor M. An audit of the immunosuppressive management of ulcerative colitis. A retrospective chart review from a referral Day-Hospital of Gastro-enterology. Minerva Gastroenterol Dietol 2002; 48: 11520.
  • 25
    Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 738.
  • 26
    Actis GC, Rossetti S, Rizzetto M, Fadda M, Palmo A. Need for hospital admission in patients with ulcerative colitis during maintenance with azathioprine. Minerva Gastroenterol Dietol 2004; 50: 97101.
  • 27
    Huguet Malaves JM, Ruiz Sanchez L, Dura Ayet AB, et al. Effectiveness of maintenance azathioprine therapy without oral cyclosporine after severe attacks of ulcerative colitis refractory to endovenous steroids. Gastroenterol Hepatol 2008; 31: 2804.
  • 28
    Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 31724.
  • 29
    Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005; 21: 82939.
  • 30
    Casson DH, Davies SE, Thomson MA, Lewis A, Walker-Smith JA, Murch SH. Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease. Aliment Pharmacol Ther 1999; 13: 8915.
  • 31
    Mahadevan U, Tremaine WJ, Johnson T, et al. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol 2000; 95: 34638.
    Direct Link:
  • 32
    Theodor E, Gilon E, Waks U. Treatment of ulcerative colitis with azathioprine. Br Med J 1968; 4: 7413.
  • 33
    Bianchi Porro G, Petrillo M, Ardizzone S, Dersideri S. Azathioprine in the treatment of ulcerative colitis. J Clin Gastroenterol 1991; 13: 1134.
  • 34
    Campbell S, Ghosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 2001; 13: 10736.
  • 35
    Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 71722.
  • 36
    Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25: 3303.
  • 37
    Aresu G, Mereu S, Frongia N, Casula G, Uccheddu A. Immunosuppressive therapy in ulcerative rectocolitis. Long-term assessment of results. Minerva Med 1982; 73: 76786.
  • 38
    Bastida Pa G, Nos Mate P, Aguas Peri M, Beltran Niclos B, Rodriguez Sole M, Ponce Garcia J. Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease. Gastroenterol Hepatol 2007; 30: 5116.
  • 39
    Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001; 13: 1297301.
  • 40
    Christodoulou D, Katsanos K, Baltayannis G, Tzabouras N, Tsianos EV. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece. Hepatogastroenterology 2003; 50: 10214.
  • 41
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.
  • 42
    Falasco G, Zinicola R, Forbes A. Review article: Immunosuppressants in distal ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 1817.
  • 43
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 4859.
  • 44
    George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6- mercaptopurine. Am J Gastroenterol 1996; 91: 17114.
  • 45
    Gisbert JP, Nino P, Cara C, Rodrigo L. Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008; 28: 22838.
  • 46
    Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2005; 39: 216.
  • 47
    Ryzhikh AN, Levitan MK, Kovtunovich LG, Drozdov VN, Marko OP. Effect of sulfasalizine with azathioprine on some immunologic indices in patients with nonspecific ulcerative colitis. Klin Med (Mosk) 1970; 48: 725.
  • 48
    Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003; 38: 7406.
  • 49
    Hinojosa J, Moles JR, Nos P, et al. Efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease. Rev Esp Enferm Dig 1995; 87: 77580.
  • 50
    Jones RA. Immunosuppressive therapy in ulcerative colitis. Proc R Soc Med 1969; 62: 499501.
  • 51
    Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999; 28: 548.
  • 52
    Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 2000; 62: 24954.
  • 53
    Kull E, Beau P. Compared azathioprine efficacy in ulcerative colitis and in Crohn’s disease. Gastroenterol Clin Biol 2002; 26: 36771.
  • 54
    Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004; 99: 4625.
    Direct Link:
  • 55
    Lobo AJ, Foster PN, Burke DA, Johnston D, Axon AT. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990; 33: 3747.
  • 56
    Lopez-Sanroman A, Bermejo F, Carrera E, Garcia-Plaza A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1616.
  • 57
    Mantzaris GJ, Archavlis E, Kourtessas D, Amberiadis P, Triantafyllou G. Oral azathioprine for steroid refractory severe ulcerative colitis. Am J Gastroenterol 2001; 96: 27978.
    Direct Link:
  • 58
    Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99: 11228.
    Direct Link:
  • 59
    Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000; 95: 12017.
    Direct Link:
  • 60
    Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 17519.
  • 61
    Sood A, Midha V, Sood N, Bansal M. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol 2006; 12: 73326.
  • 62
    Steinhart AH, Baker JP, Brzezinski A, Prokipchuk EJ. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 1990; 12: 2715.
  • 63
    Theodor E, Niv Y, Bat L. Imuran in the treatment of ulcerative colitis. Am J Gastroenterol 1981; 76: 2626.
  • 64
    Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990; 117: 80914.
  • 65
    Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992; 305: 202.
  • 66
    Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 969.
  • 67
    Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284: 12912.
  • 68
    Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 4753.
  • 69
    Caprilli R, Carratu R, Babbini M. A double-blind comparison of the effectiveness of azathioprine and sulfasalzine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis 1975; 20: 11520.
  • 70
    Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 62730.
  • 71
    Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 122733.
  • 72
    Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo- controlled, randomized trial. Indian J Gastroenterol 2000; 19: 146.
  • 73
    Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 2704.
  • 74
    Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 2003; 22: 7981.
  • 75
    Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 2000;(2): CD000067.
  • 76
    Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 94087.
  • 77
    Peppercom MA. 6-Mercaptopurine for the management of ulcerative colitis: a concept whose time has come. Am J Gastroenterol 1996; 91: 168990.
  • 78
    Korelitz BI. A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at The Mount Sinai Hospital. Mt Sinai J Med 2000; 67: 21426.
  • 79
    Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 14: 1699708.
  • 80
    Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006; 55: 43741.
  • 81
    Naganuma M, Hibi T. Do immunosuppressants really work as maintenance therapy after the achievement of remission of severe ulcerative colitis? J Gastroenterol 2002; 37: 3157.
  • 82
    Hutfless SM, Weng X, Liu L, Allison J, Herrinton LJ. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007; 133: 177986.
  • 83
    Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol 2000; 95: 195560.
    Direct Link:
  • 84
    Markowitz J, Grancher K, Mandel F, Daum F. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am J Gastroenterol 1993; 88: 448.
  • 85
    Stack WA, Williams D, Stevenson M, Logan RF. Immunosuppressive therapy for ulcerative colitis: results of a nation- wide survey among consultant physician members of the British Society of Gastroenterology. Aliment Pharmacol Ther 1999; 13: 56975.
  • 86
    Meuwissen SG, Ewe K, Gassull MA, et al. IOIBD questionnaire on the clinical use of azathioprine, 6- mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000; 12: 138.
  • 87
    Metge CJ, Blanchard JF, Peterson S, Bernstein CN. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. Am J Gastroenterol 2001; 96: 334855.
    Direct Link:
  • 88
    Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol 2003; 3: 10.
  • 89
    Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 2005; 100: 135761.
    Direct Link:
  • 90
    Caprilli R, Angelucci E, Cocco A, et al. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Dig Liver Dis 2005; 37: 40717.
  • 91
    Yip JS, Woodward M, Abreu MT, Sparrow MP. How are azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis 2008; 14: 5148.
  • 92
    Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 1937.